Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

4.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pseudolymphomatous Granuloma Annulare Rich in B Lymphocytes.

Dermatopathology (Basel, Switzerland)·2026
Same author

Rare Presentation of TEN-Like Subacute Cutaneous Lupus Erythematosus Occurring in the Setting of Donepezil Exposure and COVID-19 Infection: A Diagnostic Challenge.

Journal of cutaneous pathology·2026
Same author

Tumors With GNAQ Mutations: A Review With a Focus on Possible Shared Neural Crest Origins.

The American Journal of dermatopathology·2025
Same author

Immunohistochemical Evaluation of the Quantity of Plasma Cells and Their Distribution Pattern in Zoon's Balanitis.

The American Journal of dermatopathology·2025
Same author

Concepts in Cutaneous Vasculitis.

The American Journal of dermatopathology·2025
Same author

PIK3CA Mutation in FAVA of Adults With Unusual Anatomical Localization.

The American Journal of dermatopathology·2025

Related Experiment Video

Updated: Jul 18, 2025

Combining Reflectance Confocal Microscopy with Optical Coherence Tomography for Noninvasive Diagnosis of Skin Cancers via Image Acquisition
09:37

Combining Reflectance Confocal Microscopy with Optical Coherence Tomography for Noninvasive Diagnosis of Skin Cancers via Image Acquisition

Published on: August 18, 2022

2.4K

CD30 in Cutaneous Pathology.

Angel Fernandez-Flores1,2,3, David Cassarino4

  • 1Dermatopathologist, Department of Histopathology, University Hospital El Bierzo, Ponferrada, Spain.

The American Journal of Dermatopathology
|August 25, 2023
PubMed
Summary

The discovery of CD30 as a diagnostic marker aids in identifying lymphomas, solid tumors, and benign conditions. Its therapeutic potential is growing with targeted anti-CD30 treatments for CD30+ cancers.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.5K

Related Experiment Videos

Last Updated: Jul 18, 2025

Combining Reflectance Confocal Microscopy with Optical Coherence Tomography for Noninvasive Diagnosis of Skin Cancers via Image Acquisition
09:37

Combining Reflectance Confocal Microscopy with Optical Coherence Tomography for Noninvasive Diagnosis of Skin Cancers via Image Acquisition

Published on: August 18, 2022

2.4K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.5K

Area of Science:

  • Immunology
  • Dermatology
  • Oncology

Background:

  • CD30 is a crucial diagnostic marker identified in various lymphomas, solid tumors, and benign conditions.
  • The significance of CD30 extends beyond diagnosis, particularly in therapeutic applications for CD30-expressing malignancies.
  • Numerous CD30-positive cutaneous disorders and tumors have been classified since the marker's discovery.

Purpose of the Study:

  • To explore the historical context of CD30 discovery.
  • To review CD30-related cutaneous pathology.
  • To discuss the therapeutic implications of targeting CD30 in modern treatments.

Main Methods:

  • Literature review of historical data on CD30.
  • Analysis of studies categorizing CD30+ cutaneous disorders.
  • Examination of research on targeted anti-CD30 therapies.

Main Results:

  • CD30's role as a diagnostic marker for diverse conditions is well-established.
  • A growing number of CD30+ skin conditions are recognized.
  • Targeted therapies against CD30+ cells show therapeutic promise.

Conclusions:

  • CD30 is vital for diagnosing and understanding various neoplasms and reactive conditions.
  • Cutaneous CD30+ pathologies are increasingly recognized and relevant for targeted therapy.
  • The therapeutic targeting of CD30 represents a significant advancement in treating CD30-driven diseases.